- Appointment of Maria Wiltz as Director in charge of Group Business Development Strategy at METabolic EXplorer as part of its strategic transformation plan (IN FRENCH).
- Valbiotis: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes.
- Valbiotis presents the full results of the Phase II/III REVERSE-IT study : impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes, a first for a non-drug active substance.
We use cookies to guarantee the best experience on our site, to make statistics, to offer you third party services such as video like Youtube, social networks sharing. By clicking on validate and closing this banner, you accept the deposit of cookies.AcceptRefuseMore information
You can revoke your consent at any time by using the "Revoke Consent" button.Revoke consent
